-
-
-
[1] Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner[J]. Blood, 2005, 105(6): 2473-9. [2] Olivieri J, Coluzzi S, Attolico I, et al. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside[J]. Scientific World Journal, 2011, 11: 1908-31. [3] Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib[J]. Leuk Lymphoma, 2012, 53(6): 10 84-9. [4] Sinai P, Berg RE, Haynie JM, et al. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo[J]. J Immunol, 2007, 178(4): 2028-37. [5] Mumprecht S, Matter M, Pavelic V, et al. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections[J]. Blood, 2006, 10 8(10): 3406-13. [6] Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment[J]. Blood, 2008, 111(11): 5342-9. [7] Catellani S, Pierri I, Gobbi M, et al. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with antileukemic reactivity in patients with chronic myelogenous leukemia[J]. PloS One, 2011, 6(4): e18925. [8] Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment[J]. Leuk Lymphoma, 2006, 47(1): 155-7. [9] Thia TJ, Tan HH, Chuah TH, et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection[J]. Singapore Med J, 2008, 49 (3): e86-9. [10] Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review[J]. Int J Hematol, 2009, 90(3): 383-7. [11] Kim SG, Chun JM, Jin R, et al. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports[J]. Transplant Proc, 2010, 42(3): 843-5. [12] Wang YD, Cui GH, You Y, et al. Reactivation of chronic hepatitis B infection related to imatinib mesylatetherapy in patients with chronic myeloid leukemia: two cases report and literatures review[J] Zhonghua Xue Ye Xue Za Zhi, 2012, 33(9): 743-6.[ ŵ , , Ӿ, . Ѫ ײ ټ ϰ[J]. л ѪҺѧ ־, 20 12, 33(9): 743-6.] [13] Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor[J]. World J Gastroenterol, 2013, 19(8): 1318-21. [14] Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors[J]. J Med Virol, 2000, 62(3): 299-307. [15] Committee of exports on antiviral therapy of chronic hepatitis B. Experts consensus on antiviral therapy of chronic hepatitis B[J]. Zhonghua Shi Yan He Lin Chuang Gan Ran Bing Za Zhi(Dian Zi Ban) , 2010, 4(1): 82-91. [ ר ίԱ . ר ҹ ʶ[J]. л ʵ ٴ Ⱦ ־( Ӱ ), 2010, 4(1): 82-91.] [16] Tan J, Zhou J, Zhao P, et al. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs[J]. Clin Rheumatol, 2012, 31 (8): 1169-75.
下载:
